AU2000239309A1 - Insulin and igf-1 receptor agonists and antagonists - Google Patents

Insulin and igf-1 receptor agonists and antagonists

Info

Publication number
AU2000239309A1
AU2000239309A1 AU2000239309A AU3930900A AU2000239309A1 AU 2000239309 A1 AU2000239309 A1 AU 2000239309A1 AU 2000239309 A AU2000239309 A AU 2000239309A AU 3930900 A AU3930900 A AU 3930900A AU 2000239309 A1 AU2000239309 A1 AU 2000239309A1
Authority
AU
Australia
Prior art keywords
insulin
antagonists
peptides
igf
therapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000239309A
Other languages
English (en)
Inventor
James Beasley
Arthur J Blume
Jakob Brandt
Renee Brissette
Weiqing Cheng
Per Hertz Hansen
Ku-Chuan Hsiao
Wlodek S. Mandecki
Soren Ostergaard
Renuka Pillutla
Mark Ravera
Lauge Schaffer
Jane Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
DGI BioTechnologies LLC
Original Assignee
Novo Nordisk AS
DGI BioTechnologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, DGI BioTechnologies LLC filed Critical Novo Nordisk AS
Publication of AU2000239309A1 publication Critical patent/AU2000239309A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2000239309A 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists Abandoned AU2000239309A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/008528 WO2001072771A2 (en) 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists

Publications (1)

Publication Number Publication Date
AU2000239309A1 true AU2000239309A1 (en) 2001-10-08

Family

ID=21741219

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000239309A Abandoned AU2000239309A1 (en) 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists

Country Status (6)

Country Link
EP (2) EP1383793B1 (enExample)
JP (1) JP2004512010A (enExample)
AT (1) ATE529435T1 (enExample)
AU (1) AU2000239309A1 (enExample)
CA (1) CA2402780A1 (enExample)
WO (1) WO2001072771A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
DE60217066T4 (de) 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
CA2439735A1 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
AU2004278311A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. IGF binding proteins
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
WO2006047214A2 (en) * 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
EP2281841A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarkers for pre-selection of patients for anti-IGF1R therapy
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis
AU2006264567A1 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US7659362B2 (en) * 2006-05-30 2010-02-09 Academia Sinica Metal-binding motif compositions and methods
WO2008133961A2 (en) 2007-04-24 2008-11-06 Antyra Inc. Igf-1r binding proteins and antagonists
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
JP2014156401A (ja) * 2011-05-25 2014-08-28 Hoya Corp Ｉｇｆ−１ｒ結合性ペプチド
CN111377773A (zh) * 2020-04-16 2020-07-07 山东省现代中药研究院有限公司 一种含内生菌的花生用海藻复合微生物有机肥

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6010861A (en) 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
DE4432943A1 (de) * 1994-09-15 1996-03-21 Radulescu Razvan T Dr Med M D Numerical Mirror Image Strategy (NUMIS)
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
JPH11506722A (ja) * 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン 細胞に核酸を送達するための核酸運搬体
RU2078769C1 (ru) * 1995-08-18 1997-05-10 Научно-исследовательский институт биомедицинской химии РАМН Пептидный фрагмент, обладающий биологической активностью инсулина
US5912160A (en) * 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
WO1997046683A2 (en) * 1996-06-07 1997-12-11 Genetics Institute, Inc. Polynucleotides encoding secreted proteins
JP2002512685A (ja) * 1997-01-15 2002-04-23 テリック・インコーポレイテッド インスリン受容体活性のモジュレーター
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US7020563B1 (en) * 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
AU2321999A (en) * 1998-01-16 1999-08-02 Genzyme Corporation Adenoviral vectors with modified capsid proteins
WO2000006717A2 (en) * 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein

Also Published As

Publication number Publication date
EP1383793A2 (en) 2004-01-28
CA2402780A1 (en) 2001-10-04
WO2001072771A3 (en) 2003-12-04
WO2001072771A2 (en) 2001-10-04
ATE529435T1 (de) 2011-11-15
EP2368902A3 (en) 2011-12-21
JP2004512010A (ja) 2004-04-22
EP1383793B1 (en) 2011-10-19
EP2368902A2 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
WO2003070747A3 (en) Insulin and igf-1 receptor agonists and antagonists
EP2368902A3 (en) Insulin and IGF-1 receptor agonists and antagonists
PT2241575E (pt) Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos
WO2002072780A3 (en) Igf antagonist peptides
WO2003040309A3 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
AU2003242352A8 (en) Adiponectin receptor and gene coding for the same
MA31242B1 (fr) Co-agonistes des recepteurs du glucagon/glp-1
EP1251137A3 (en) Use of insulin-like growth factor agonist peptides
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
MX9700822A (es) Composicion cosmetica que contiene un antagonista de los receptores del neuropeptido y.
IL181311A (en) Variants of neoblastin polypeptide, dimers, conjugates, and fusion proteins that include them, pharmacological compounds based on them, nucleic acids encoding them, and vectors - expression including said nucleic acids, cells containing said vectors, methods for making and using said polypeptides
DK1282437T3 (da) Behandling af brusklidelser
DE69720207D1 (de) Peptide mit spezifischer affinität für pacap typ 1 rezeptoren
WO2005009358A3 (en) Conformationally constrained parathyroid hormone (pth) analogs
WO2001059117A3 (en) Seven-transmembrane proteins/g-protein coupled receptors
Abribat et al. Characterization of [125I-Tyr10] human growth hormone-releasing factor (1–44) amide binding to rat pituitary: evidence for high and low affinity classes of sites
GR3030152T3 (en) A human t-cell receptor of the g-protein coupled receptor family
Land et al. Assay for galanin receptor
ZA987475B (en) Nitrogen substituted imidazo [4,5-c] pyrazoles as corticotropin releasing hormone antagonists.
WO2001049847A3 (en) 26904, 38911, and 39404, seven-transmembrane proteins/g-protein coupled receptors
WO2000050563A3 (en) G protein-coupled receptor resembling galanin receptors
GB0315182D0 (en) Cytokine variant polypeptides
WO2005075021A3 (en) Chemically-modified human growth hormone receptor antagonist conjugates
WO2004009775A3 (en) Methods and compositions relating to chimeric nicotinic receptor subunits
WO2001048483A3 (en) Method for screening of appetite control agents